Sugi Predict

Sugi Predict / Compounds / SCHEMBL22325311

SCHEMBL22325311

SCHEMBL22325311

COc1cc2nccnc2cc1-c1ccc(Cl)nn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 6/20 0.45
▸ PDE4B Q07343 1/20 0.40
▸ PDE10A Q9Y233 1/20 0.40
▸ PDGFRB P09619 1/20 0.38
▸ PDGFRA P16234 1/20 0.38
▸ CCNB2 O95067 1/20 0.35
▸ CDK1 P06493 1/20 0.35
▸ CCNB1 P14635 1/20 0.35
▸ GSK3A P49840 1/20 0.35
▸ GSK3B P49841 1/20 0.35
▸ CDK5 Q00535 1/20 0.35
▸ CDK5R1 Q15078 1/20 0.35
▸ CCNB3 Q8WWL7 1/20 0.35
▸ SRC P12931 2/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ POLB P06746 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ ALDH1A1 P00352 3/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22325314 0.86 PDE4B (0.38) MAOBPDE4BPDE10AMEN1KMT2A
SCHEMBL22325313 0.78 MEN1 (0.37) MAOBPDE4BCCNB2CDK1CCNB1
SCHEMBL31488629 0.78 MEN1 (0.37) MAOBPDE4BCCNB2CDK1CCNB1
SCHEMBL348140 0.70 PDGFRB (0.59) PDGFRBPDGFRACCNB2CDK1CCNB1
SCHEMBL3124663 0.69 G6PD (0.44) MAOBPDE4BMEN1KMT2APOLB
SCHEMBL25104907 0.68 MAOB (0.37) MAOBPDE4BPDE10ARAB9AALDH1A1
SCHEMBL15476264 0.68 SMN1; SMN2 (0.44) MAOBPDE4BSMN1; SMN2
SCHEMBL11010002 0.68 BRD4 (0.48) MAOBPDGFRBMEN1KMT2AALDH1A1
SCHEMBL1744281 0.68 MEN1 (0.53) PDE4BMEN1KMT2APOLBRAB9A
SCHEMBL24408623 0.67 QPCT (0.42) MAOBPDE4BSRCMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12522597-B2 Methods and compositions for modulating splicing SKYHAWK THERAPEUTICS, INC. (US) 2026-01-13 — — US disclosed
CN-119638696-A Methods and compositions for modulating splicing 斯基霍克疗法公司 2025-03-18 — — CN disclosed
US-20230054781-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-02-23 — — US disclosed
US-20230054781-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-02-23 — — US disclosed
EP-3921311-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING Skyhawk Therapeutics, Inc. (US) 2021-12-15 — — EP disclosed
CN-113661162-A Methods and compositions for modulating splicing 斯基霍克疗法公司 2021-11-16 — — CN disclosed
WO-2020163647-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. (US) 2020-08-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230054781-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 MAOB 3887/4885PDE4B 948/4885PDE10A 1359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.